JOLTS Beat | Retail Goes All-In | SEC Targets ETFs | AI Chip Startup Emerges

The Nasdaq is up 20 percent this quarter. The S&P 500 up 14 percent. The Dow rose 13 percent. All three the best quarters since Q2 2020. That was the COVID rebound quarter, which tells you something about the energy of this one.

Tech stocks are higher again. Semiconductor names are leading. The PHLX Semiconductor Index is up 81 percent this quarter. Its best quarter ever. Gold is heading for its worst quarter since 2013. The yen hit a 40-year low. Japan is on intervention watch.

Investor Signal

This quarter delivered an Iran war, a Fed pivot, a Supreme Court battle, and a historic tech selloff. Markets still finished near the highs. Apollo's chief economist said at the ECB Forum today that hyperscaler AI debt is crowding out Treasury demand. That's the risk heading into Q3. Warsh speaks Wednesday. Payrolls land Thursday. Markets close Friday.

Some stocks are built for a quarter… others for a lifetime.

Our 7 Stocks to Buy and Hold Forever report reveals companies with the strength to deliver year after year - through recessions, rate hikes, and even the next crash.

One is a tech leader with a 15% payout ratio - leaving decades of room for dividend growth. 

Another is a utility that’s paid every quarter for 96 years straight. 

And that’s not all - we’ve included 5 more companies that treat payouts as high priority.

These are the stocks that anchor portfolios and keep paying.

This is your chance to see all 7 names and tickers - from a consumer staples powerhouse with 20 years of outperformance to a healthcare leader with 61 years of payout hikes. 

The report is free for a limited time - go here to get it now.

Job openings came in at 7.594 million in May. Economists expected 7.30 million. That's the largest beat in months. It looks great heading into Thursday's payrolls on the surface.

Here's the nuance. Hiring fell 45,000. Layoffs rose. The gap between people who say jobs are "plentiful" versus "hard to get" dropped to its lowest since early 2021. Workers no longer feel like jobs are everywhere. That typically precedes a real hiring slowdown by 60 to 90 days.

Consumer confidence ticked up slightly in June as gas prices fell. Still came in below expectations though. The consumer is hanging in, not celebrating.

The Payroll Setup

Thursday's consensus is 110,000 jobs added. This JOLTS print biases toward a headline beat but the underlying picture is softening. A clean beat on both jobs and unemployment at 4.3 percent confirms the labor market is carrying the Warsh framework. A miss on either creates the first real crack in that story.

Citadel Securities reported that retail investors bought nearly three-and-a-half times the average daily amount on every S&P 500 down day this year. The strongest dip-buying behavior since Citadel started tracking in 2020. It eclipsed the 2021 meme-stock peak. June alone is on pace to be the strongest retail trading month in Citadel's history.

The biggest single day of net buying happened on June 12. SpaceX's (SPCX) IPO day. Retail bought $1.9 billion in semiconductor options premium per day in June. Six times the historical average. Seventy-five percent of that activity was call options.

Citadel's own head of equity strategy called this "a structural feature of modern markets." Retail isn't trading around the AI thesis. Retail is the marginal buyer driving it.

The Risk Underneath

The same concentration that powered the SOX up 81 percent this quarter creates conditions for accelerated downside. If AI capex returns disappoint earnings, seventy-five percent in calls means retail is positioned for one outcome only. That positioning unwinds fast.

For a moment…

Forget about Trump’s ties to Israel.

Forget about reports of Iran’s nuclear program.

Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.

Click here to find out what it is.

If you have even a single dollar invested in the U.S. stock market, this is going to directly impact you.

Discover the reason here.

The SEC opened a 60-day comment period on a comprehensive review of ETF regulation. The industry has grown to $16 trillion. The SEC currently has essentially one enforcement tool if it doesn't like an ETF: suspend its shares. That's it.

The review specifically addresses confidentiality. Right now ETF applications are public immediately. Competitors file copycat products before the original even launches. The SEC wants to change that.

What the Review Covers

The confidentiality fix sounds procedural. It's not. Novel AI infrastructure ETFs, prediction market vehicles, and leveraged semiconductor products could all launch under a meaningfully different regulatory architecture by Q4.

If the SEC announces new tools targeting leveraged single-stock or 3X semiconductor ETFs specifically, the products driving retail concentration in chip options face their first real regulatory constraint.

The Leverage Signal

Additional enforcement tools announced alongside the comment period close names the framework restructuring as active intervention. That's when the ETF review becomes a market event rather than a regulatory filing.

Etched was founded in 2022 to compete with Nvidia (NVDA) in AI inference chips. It just emerged from stealth with $800 million raised, $1 billion in customer contracts signed, and Jane Street as a new investor. TSMC's venture arm invested too. Stanley Druckenmiller, Geoffrey Hinton, and Fei-Fei Li are all backers.

Inference is the key word. That's the compute required to serve AI answers to real users in real time. Different from training, which Nvidia currently dominates. Etched is betting the inference market splits away from the training market and requires purpose-built chips.

The $1 billion in contracts before even shipping is the headline. It names supply-constrained demand in a category that didn't exist as an institutional investment category 18 months ago.

The Inference Stack

OpenAI built Jalapeño with Broadcom (AVGO) for inference. Google (GOOGL) is redirecting chips toward inference. Groq licensed its technology to Nvidia for inference. Etched raised $800 million for inference. The category is being built from every direction at once.

The Customer Test

Named hyperscaler or major AI lab customers announced within 60 days converts the $1 billion contract figure into specific institutional adoption. That's the number that moves Nvidia's valuation conversation.

Donald Trump has cheated death.

He’s overcome insane and criminal vote rigging.

And survived every indictment and impeachment thrown at him.

But his next move could make him a legend – and perhaps the most popular president in U.S. History.

Former Presidential Advisor, Jim Rickards says, “Trump is on the verge of accomplishing something no President has ever done before."

And if he’s successful, it could kick off one of the greatest wealth booms in history.

We recently sat down with Rickards to capture all the key details on tape.

For the moment, you can watch this interview free of charge – just click here.

The House Select Committee on China opened bipartisan investigations into Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol-Myers Squibb (BMY) over clinical trials at Chinese military hospitals and Xinjiang sites. Documentation required by July 17.

Merck conducted at least 31 trials in Xinjiang and 40 at military-affiliated medical centers. AbbVie ran trials at 17 Xinjiang sites and 16 military centers. The concern is that cutting-edge U.S. biotech intellectual property is being transferred to the Chinese military through these research relationships.

This arrives the same day Lilly and Regeneron (REGN) were selected for the FDA's PreCheck manufacturing fast-track program. The pharmaceutical sector is now navigating reshoring acceleration and China decoupling simultaneously. Those two pressures point in completely opposite directions.

The Structural Problem

China overtook the U.S. in early drug development by 2024. The U.S. share of global early drug development dropped to 37 percent from 48 percent in 2015. Chinese trial sites run two to five times faster than U.S. sites. Decoupling from that infrastructure has real costs the investigation doesn't address.

The Decoupling Clock

Any of the five named companies announcing China clinical trial reductions within 60 days confirms the investigation is producing operational changes, not just paperwork. That's when pharmaceutical China exposure becomes a quantified financial risk in earnings models.

Tuesday closes the best quarter in six years with five new pressure points landing at once.

JOLTS beat but underlying labor demand is softening ahead of Thursday payrolls. Retail investors set a historic dip-buying record concentrated in semiconductor calls. The SEC opened a review of the entire $16 trillion ETF industry. An AI inference chip startup emerged with $800 million and $1 billion in orders. And Congress opened a bipartisan investigation into five pharma giants over China clinical trials.

The quarter was historic. Q3 starts with a lot to answer for.